Dosing & Uses
Dosage Forms & Strengths
Intradermal solution
- 5 Unit/0.1mL
Tuberculosis
Diagnosis: Mantoux test, inject 0.1 mL (5 tuberculin units) intradermally; the result is read 48 to 72 hours after administration
Positive if 10 mm induration
Use 1 TU in sensitized patients, 250 TU if no response to 5 TU
Dosage Forms & Strengths
Intradermal solution
- 5 Unit/0.1mL
Tuberculosis
Diagnosis: Mantoux test, inject 0.1 mL (5 tuberculin units) intradermally; the result is read 48 to 72 hours after administration
Positive if 10 mm induration
Use 1 TU in sensitized patients, 250 TU if no response to 5 TU
Tuberculosis
Diagnosis: Mantoux test, inject 0.1 mL (5 tuberculin units) intradermally; the result is read 48-72 hours after administration
Positive if >10 mm induration
Use 1 TU in sensitized patients, 250 TU if no response to 5 TU
Adverse Effects
Suspected adverse events after administration of any vaccine may be reported to Vaccine Adverse Events Reporting System (VAERS), 1-800-822-7967
Frequency Not Defined
Rash
Itch
Vesiculation
Ulceration
Necrosis
Pain
Warnings
Contraindications
Previous positive tuberculin skin test responsiveness suppressed within 6 weeks of viral infection, inactive TB, immunosuppression, geriatric
Cautions
Contains soluble growth products from tubercle bacillus
Old tuberculin (OT) is culture filtrate of uniform potency
PPD is more refined and is preferred product
Multiple puncture device (Aplitest, SclavoTest-PPD, Tine Test PPD) not as sensitive
Pregnancy & Lactation
Pregnancy Category: C
Lactation: not known if excreted in breast milk
Pregnancy Categories
A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk. C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done. D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk. X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist. NA: Information not available.Pharmacology
Mechanism of Action
Antigenic purified protein derivative (PPD) of Mycobacterium tuberculosis; patients become sensitized to certain antigenic components of the M. tuberculosis organism.
Pharmacokinetics
Onset of action: 5-6hr (delayed hypersensitivity reactions)
Peak effect: 48-72 hr
Images
Patient Handout
Formulary
Adding plans allows you to compare formulary status to other drugs in the same class.
To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.
Adding plans allows you to:
- View the formulary and any restrictions for each plan.
- Manage and view all your plans together – even plans in different states.
- Compare formulary status to other drugs in the same class.
- Access your plan list on any device – mobile or desktop.
